By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regen BioPharma  

4700 Spring Street
Suite 304
La Mesa  California  91942  U.S.A.
Phone: 619-702-1404 Fax: 619-330-2328


Company News
FDA Issues IND Number For Regen BioPharma 's dCellVax Therapeutic Application, A Proposed Treatment For Breast Cancer 11/4/2014 11:02:15 AM
Regen BioPharma 's Chief Scientific Officer Examines Potential Role Of Immunotherapeutic Treatment For Ebola In Conjunction With Other Current Therapies 10/29/2014 11:54:17 AM
Cell Therapy Expert Dr. Amit Patel Joins Regen BioPharma Scientific Advisory Board 10/15/2014 11:23:16 AM
Regen BioPharma Files IND Application With FDA For dCellVax Breast Cancer Immune Therapy 10/8/2014 10:44:37 AM
Regen BioPharma Completes Preclinical Experiments For dCellVax Breast Cancer Immune Therapy 10/2/2014 11:02:44 AM
Regen BioPharma Files Patent Application On New Therapy That Uses the "Innate" Immune System To Kill Cancer 9/17/2014 9:43:19 AM
Regen BioPharma Provides Update On HemaXellerate IND Progress After Conference Call With FDA 9/12/2014 11:49:37 AM
Regen BioPharma Provides Update On dCellVax Breast Cancer Immunotherapy 8/5/2014 10:50:45 AM
Bio-Matrix Scientific Group Inc. (BMSN.OB) Subsidiary Regen BioPharma Collaborates On Research Paper Analyzing The Use Of Gene Silencing In Heart Transplants 6/12/2014 10:17:07 AM
Regen BioPharma , A Majority Owned Subsidiary Of Bio-Management, Provides Update On Hemaxellerate I™ IND For Treatment Of Drug Resistant Aplastic Anemia 5/13/2014 10:05:10 AM